The U.S. pharmaceutical CDMO market is estimated at USD 39.14 billion in 2025 and is projected to reach approximately USD 68.57 billion by 2034, expanding at a CAGR of 6.43% over the forecast period. According to a study by Towards Healthcare, a sister firm of Precedence Research, the U.S. pharmaceutical CDMO market was valued at USD 36.77 billion in 2024 and is projected to reach approximately USD 68.57 billion by 2034, growing at a CAGR of 6.43%. The rising commercial scale-up in different therapeutic areas in the US and growing adoption of digital technologies are fueling overall market expansion. By product, the API segment dominated the U.S. pharmaceutical CDMO market in 2024 and is expected to grow fastest during the forecast period. By workflow, the commercial segment held the largest revenue share of the market in 2024. By application, the oncology segment registered dominance in the market in 2024. By end-use, the large pharmaceutical companies segment was dominant in the U.S. pharmaceutical CDMO market in 2024 and is expected to grow rapidly in the study years. Companies that are offering comprehensive services to different pharmaceutical and biotechnology companies, including both drug development and manufacturing in the US, are referred to as U.S. pharmaceutical CDMO market. Primarily, they provide expertise and resources for these companies. In 2025, they are focusing on novel drug discovery and development in oncology and other chronic conditions with the increased adoption of advanced production technologies. Moreover, the US is widely investing in robust and advanced infrastructure to fulfil the requirements of the increasing demand for specialized services, particularly in areas like biologics, sterile injectables, and gene and cell therapies. The U.S. pharmaceutical CDMO market has major dominating factors in its expansion, including crucial support to small and mid-sized pharmaceutical companies. These companies are facing the limitations of infrastructure for large-scale production with enhanced dependence on CDMOs for numerous stages of development and manufacturing. Also, benefits of pharmaceutical CDMOs, like scalability, flexibility, and cost-effectiveness, are fueling the expansion of the market with reduced capital investments. Besides this, experts working in CDMOs can navigate the complex regulatory landscape and check the compliance with standards like GMP (Good Manufacturing Practices). Different companies in the US are highly adopting outsourcing production to CDMOs to handle expenses and emphasize on competencies. Alongside, continuous advances in technologies and regulatory frameworks also play a crucial role in this market development. Challenges connected with the U.S. pharmaceutical CDMO market include geopolitical stress, lack of raw material, and pandemic-related disturbances, which are barriers in the production and delivery. Along with this, the rising need for a skilled workforce and specialized knowledge in continuous manufacturing and advanced bioprocessing demands vital investment in training and development. The U.S. pharmaceutical CDMO market is experiencing widespread expansion due to broader demand for a variety of biologics and biosimilars which are used in novel rare cases and other severe health issues. Besides this, ongoing technological breakthroughs in process chemistry and manufacturing automation are boosting the efficiency and quality of drug production, further propelling the adoption of CDMO services. As well as escalating cases of diverse cancers is assisting the development of novel cancer therapies, including targeted therapies and immunotherapies. In June 2025, Agenus Inc., a U.S.-based biotechnology company specializing in immuno-oncology, entered into a partnership with $141M Zydus investment to transform the immune-oncology area. In July 2025, ESTEVE acquired Regis Technologies, a United States-based Contract Development and Manufacturing Organization (CDMO), to accelerate its contract development and manufacturing services for small-molecule active pharmaceutical ingredients from pre-clinical to commercial manufacturing in the US. In May 2025, Purdue University and a collaboration of leaders in AI, pharmaceutical manufacturing, and public policy launched a national effort in the Dirksen Senate Office Building to boost pharmaceutical manufacturing in the United States by revealing cutting-edge AI and advanced manufacturing technologies. In May 2025, Benuvia Operations, LLC, a U.S.-based global Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) supplier, signed a multi-year supply agreement with a prominent U.S. pharmaceutical company to support the company's product development activities. Key players in the U.S. pharmaceutical CDMO market include Adare Pharma Solutions, AGC Biologics, Agilent Technologies, Catalent Pharma Solutions, Exela Pharma Sciences, PCI Pharma Services, Pfizer CentreOne, Scorpius BioManufacturing, Sharp Services, Thermo Fisher Scientific, and UPM Pharmaceuticals, Inc. The global bioconjugation market reached USD 5.52 billion in 2024, rose to USD 6.37 billion in 2025, and will likely hit USD 23.18 billion by 2034, expanding at a CAGR of 15.46% from 2025 to 2034. The U.S. residual DNA testing market continues its upward trajectory and is set to generate substantial revenue growth, potentially reaching hundreds of millions by 2034. The worldwide life science CDMO market is expanding significantly and is projected to record several hundred million dollars in additional revenue by the end of the forecast period from 2025 to 2034. The global veterinary CRO and CDMO market stood at USD 7.17 billion in 2024, increased to USD 7.77 billion in 2025, and will likely reach USD 16.13 billion by 2034, growing at a CAGR of 8.43% between 2025 and 2034. The global investigational new drug CDMO market measured USD 5.29 billion in 2024, rose to USD 5.66 billion in 2025, and is forecast to reach USD 10.34 billion by 2034, expanding at a CAGR of 6.97% during the same period. The global advanced therapy medicinal products CDMO market stood at USD 6.73 billion in 2024, grew to USD 7.99 billion in 2025, and will likely surge to USD 37.27 billion by 2034, posting a CAGR of 18.82% between 2025 and 2034. The global mRNA therapeutics CDMO market valued at USD 4.62 billion in 2024, increased to USD 5.15 billion in 2025, and is projected to reach USD 13.63 billion by 2034, growing at a CAGR of 11.37% from 2025 to 2034. The CDMO services for pharma and biotech market is posting substantial growth from 2024 to 2034, fueled by rising outsourcing trends among pharmaceutical and biotech companies. The CDMO aseptic filling solutions market is recording robust growth and will continue booming through the forecast period, driven by growing demand for sterile manufacturing and specialized injectable therapies. The active pharmaceutical ingredients CDMO market stood at USD 127.45 billion in 2024, rose to USD 136.92 billion in 2025, and is projected to reach USD 260.98 billion by 2034, expanding at a CAGR of 7.43% from 2025 to 2034. By Product: API Type (Traditional API, Highly Potent API, Antibody-drug conjugate (ADC), Others), Synthesis (Synthetic, Solid, Liquid), Biotech Drug (Innovative, Generics), Manufacturing (Continuous Manufacturing, Batch Manufacturing), Drug Product (Oral Solid Dose, Semi-Solid Dose, Liquid Dose, Others). By Workflow: Commercial, Clinical. By Application: Oncology, Small Molecules, Biologics, Infectious Diseases, Neurological Disorders, Cardiovascular Disease, Metabolic Disorders, Autoimmune Diseases, Respiratory Diseases, Ophthalmology, Gastrointestinal Disorders, Hormonal Disorders, Hematological Disorders, Others. By End-Use: Large Pharmaceutical Companies, Medium Pharmaceutical Companies, Small Pharmaceutical Companies. Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

U.S. Pharmaceutical CDMO Market Valuation to Surpass USD 68.57 Billion by 2034

The U.S. pharmaceutical CDMO market is projected to grow from USD 39.14 billion in 2025 to USD 68.57 billion by 2034, at a CAGR of 6.43%. This growth is driven by rising demand in therapeutic areas like oncology and chronic conditions, increased adoption of digital technologies and advanced manufacturing, and the outsourcing of production by pharmaceutical companies to leverage scalability, cost-effectiveness, and regulatory expertise. Key trends include expansion in biologics, gene and cell therapies, and the growing role of AI in manufacturing. Major developments include Agenus Inc.'s $141M partnership with Zydus, ESTEVE's acquisition of Regis Technologies, and Purdue University's collaboration on AI-driven manufacturing. The market is also seeing strong growth in specialized segments such as mRNA therapeutics, advanced therapies, and active pharmaceutical ingredients (APIs), with several sub-markets growing at higher CAGRs. Key players include Adare Pharma Solutions, AGC Biologics, Catalent Pharma Solutions, Exela Pharma Sciences, PCI Pharma Services, Pfizer CentreOne, Scorpius BioManufacturing, Sharp Services, Thermo Fisher Scientific, and UPM Pharmaceuticals, Inc.